The Leader in Personalized Anti-Cancer Therapy (“ACT”) and Cool Laser Therapy (“CLT”)
Theralase® was one of the first companies in North America to bring CLT to patients and the first company in the world to bring personalized ACT to patients individual tissue characteristics.
With our multi-discipline experience in physics, engineering, medicine, biology, chemistry, immunology, pharmaceutical drug design, finance, business development, sales, marketing and clinical study coordination, Theralase® is staffed with the talent to drive the next level of technology for personalized healthcare in oncology and pain.
Striving to continuously improve the quality of life for those afflicted with cancer and pain. Theralase®’s research, development and commercialization activities focus on safely and effectively treating oncological and pain-related conditions. Serving our corporate mandate to “Destroying Cancer at the Speed of Light®” and “Healing Pain at the Speed of Light®”.
Founded in 1994, Theralase®’s operations are divided into two main divisions: the Cool Laser Therapy (“CLT”) division focused on the research, development, production and distribution of medical laser technologies for healing pain and also researching, developing and commercializing medical laser technologies for the activation of Photo Dynamic Compounds (“PDCs”) in the Anti-Cancer Therapy (“ACT”) division and the ACT division focused on the destruction of cancer, bacteria and viruses.
Anti-Cancer Therapy Division
Theralase®’s ACT division combines Photo Dynamic Compounds (“PDCs”) with medical laser technologies safely and effectively destroy cancer, bacteria and viruses, while stimulating the immune system.
Cool Laser Therapy Division
Theralase®’s CLT division focuses on the research, development, production and distribution of Cool Laser Therapy products, Health Canada and FDA approved to eliminate knee pain and when used off-label to eliminate pain, reduce inflammation and accelerate tissue healing in numerous nerve, muscle and joint conditions.
Theralase® accomplishes its mandate of “Destroying Cancer at the Speed of Light®” and “Healing Pain at the Speed of Light®” by researching, developing and commercializing high-quality, cutting edge technology through our scientific, medical, engineering teams completing world-class preclinical and clinical research in each division. Theralase® searches for and hires experts in their respective field both as employees and consultants.
For over 25 years, the Theralase® team has been dedicated to researching, developing, manufacturing and distributing high-quality, cutting-edge medical laser technologies to healthcare practitioners to heal their patient’s conditions at an affordable price.
Working at Theralase®
Theralase® is dedicated to providing a stimulating work environment that offers growth opportunities, employee benefits and exciting challenges to develop your career to the next level.
Toronto, Ontario –November 23, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical...0
Toronto, Ontario – November 13, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinica...0
Theralase Signs Agreement with University of Manitoba to Commence Development of Coronavirus Vaccine and Therapy
Toronto, Ontario – August 19, 2020, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage...0
Toronto, Ontario – August 12, 2020, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage...0
Theralase Reports on Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) Clinical Study (“Study II”) Progress
Results of the First 12 patients enrolled in the Phase II NMIBC Clinical Study Demonstrate a 58.3% Response 90 Days Post Initial Treatment Toronto,...0